UK-432,097

UK-432,097 is a drug that was developed by Pfizer for the treatment of HIV. It is a Non-nucleoside reverse transcriptase inhibitor (NNRTI), which is a type of antiretroviral drug used to treat HIV. UK-432,097 is not currently approved for use in any country.

History

UK-432,097 was developed by Pfizer in the early 2000s as a potential treatment for HIV. It was tested in clinical trials, but development was discontinued for unknown reasons.

Mechanism of action

As an NNRTI, UK-432,097 works by inhibiting the reverse transcriptase enzyme. This enzyme is necessary for the replication of HIV. By inhibiting this enzyme, UK-432,097 prevents the virus from replicating and spreading to new cells.

Clinical trials

UK-432,097 was tested in clinical trials in the early 2000s. However, the results of these trials have not been publicly released, and it is not known why development of the drug was discontinued.

See also

• List of investigational antivirals
• Pfizer
• Non-nucleoside reverse transcriptase inhibitor
• HIV

References

UK-432,097 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski